Our Team
Rutger founded the company that created the NeuroMotor Pen (NMP).
While working with a small consulting firm, Rutger developed ideas to utilise neuroscience from his earlier PhD research to create novel, easily implementable clinical tools.
Manus Neurodynamica was founded as a channel to realise those ideas.
Rutger instigated and led the EU project, DiPAR, which delivered the initial product development and clinical validation.
Prior to his PhD, Rutger gained experience in biomedical engineering (J&J Cordis Europe, Philips DAP and Medical systems) and project management for the Dutch healthcare sector (Cap Gemini). He also has post-graduate degrees in Bioengineering and Business administration.
David guides and oversees technical and operational activities and is heavily involved in technical and product development.
David graduated in Microelectronics and Software Engineering where a collaborative project sparked his interest in neural systems.
He then studied for his PhD researching human perception of colours. Postdoctoral research in the human neural dynamics of combined sensory stimuli followed, before David joined Nonlinear Dynamics Ltd. where he led development culminating in the release of the flagship Progenesis product line and several patents. Nonlinear Dynamics, and the Progenesis line was sold to Water Corporation.
Nonlinear developed an AI solution promising a step change in hypothesis free proteomics. Biosignatures spun that IP out, with David as CEO/CTO, and the goal to use the new technology to discover novel blood biomarker panels for urological cancers.
Biosignatures was created to generate the high quality clinical data to feed into the AI. This involved management of key clinical study interactions such as IRB approval, blood sample collection and the cold chain processes leading to high quality lab analysis and biomarker panel generation.
Christoforos serves as the Senior Data Scientist of Horao Neurolabs Ltd.
He supports further research and development of the NeuroMotor Pen.
He received his PhD from Newcastle University in 2017.
His expertise includes signal processing, statistical modelling and intelligent data analysis.
Experienced CFO & Board member, most recently over 3 years at Argo Blockchain Plc - dual listed on the LSE & NASDAQ.
Responsible for all financial elements of successful NASDAQ listing.
Experience in corporate finance, particularly focus on financial due diligence. Registered Chartered Accountant.
Advisory Board
Keith Redpath
AdvisorKeith supports Horao Neurolabs and has been in the life sciences industry for over 30 years.
He graduated from Heriot Watt University in Marine Biology and gained a PhD from the University College of North Wales.
Keith has worked in pharmaceutical development at Covance, Global Head of Life Sciences at PA Consulting Group and Head of Life Sciences Equity Research at Lazard & Co.
He joined finnCap in 2007 with a mandate to build its Life Science franchise and by 2015 it became the largest in the sector on AIM.
Keith retired from his role in finnCap in April 2016.
Guy Wood-Gush
AdvisorHaving graduated in medicine from Kings College London, Guy practiced in ophthalmology and neurosurgery before moving into business leadership.
His experience includes drug development at Eli Lilly and healthcare investment banking with Barclays de Zoete Wedd and JPMorgan.
He worked on major transactions including the IPO of Zeneca and the Wellcome £2.3bn stock offering.
Guy later became Chief Executive of Cancer Research Ventures and Chairman of Cambridge Cognition Ltd.
He has also served as Chief Executive of Deontics Ltd and Trustee of the Royal Society of Medicine.
He holds an MBA from INSEAD.
Albert Nicholl
AdvisorAlbert has extensive commercial experience in healthcare having worked at senior levels within companies such as Stryker and Orthofix.
In recent years he has supported growing healthcare companies through a variety of non-executive roles.
His expertise focuses on helping companies raise investment, build high-performing teams and commercialise successfully.
Professor John Harrison
AdvisorExpert psychologist with a special interest in cognition and Principal Consultant at Metis Cognition.
John advises on the successful integration of cognitive testing into therapeutic development programs.
He is also an Associate Professor with the AUmc Alzheimer Center and Visiting Professor at King’s College London.
He holds Chartered Psychologist status and has authored/co-authored more than 80 books and scientific articles.
His publications include the neuroscience book ‘Synaesthesia: The Strangest Thing’.
Dr Terry O’Brien
AdvisorExtensive experience as a senior executive and consultant within the healthcare industry.
Terry is the Co-founder and CEO of LiDCO Group PLC.
Over the last seven years, he has provided consultancy advice to early-stage medical technology companies.
His expertise includes commercialisation and go-to-market strategy for healthcare technologies.
He holds a Ph.D. in Stem Cell Transplantation from Westminster Medical School and a Bachelor's in Human Biology from Surrey University.
Prof Richard Walker
AdvisorConsultant Physician and Honorary Professor of Ageing and International Health.
Richard is a specialist in Parkinson’s disease and healthcare of the elderly at Northumbria NHS Foundation Trust.
He serves as Clinical Lead for the Northumbria PD Service and Director of R&D for the Trust.
He is closely involved with the DeNDRoN Research Network both locally and nationally.
His main research interests include Parkinson’s disease in the UK and stroke research in Sub-Saharan Africa and Tanzania.
Prof Michael Caligiuri
AdvisorProfessor at the University of California San Diego with expertise in neurological and psychiatric disorders.
His research focuses on understanding motor function and impairment in diagnosis and treatment.
He specialises in movement disorders including tremor, dyskinesia and bradykinesia.
Prof Caligiuri has contributed significantly to differentiating degenerative disorders from medication-induced disorders.
His work has also demonstrated how antipsychotics and mood stabilizers can normalize cortical and subcortical hyperactivity in bipolar disorder.
Prof Michele Hu
AdvisorProfessor at the Nuffield Department of Clinical Neurosciences, University of Oxford.
Michele is Honorary Consultant Neurologist at Oxford University Hospitals.
She is Co-Principal Investigator of the Oxford Parkinson’s Disease Centre.
Her research focuses on biomarkers and early pathological pathways in Parkinson’s disease.
Michele’s interests include wearable technology, sleep-related neurodegeneration research and imaging the human brain.
Our Collaborators
We proudly collaborate with leading healthcare institutions, universities, research organizations, and global innovation partners.
